The history of alcohol septal ablation

Cardiovascular Revascularization Medicine

Volumn 11, Issue 4, 2010, Pages 260-261

  Kuhn, Horst J ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL SEPTAL ABLATION; HISTORY OF MEDICINE; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; LETTER; PRIORITY JOURNAL;

CARDIOMYOPATHY, HYPERTROPHIC; ETHANOL; HEART CATHETERIZATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INJECTIONS;

EID: 77957724488     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2009.11.003     Document Type: Letter

References (15)

1. Parakh N, Bhargava B Golden jubilee of hypertrophic cardiomyopathy: is alcohol septal ablation the gold standard?. Cardiovasc Revasc Med 2009, 10:172-178.
2. Sigwart U Nonsurgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995, 346:211-214.
3. Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, Bartelsmeier M, Stellbrink C Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a ten year experience. Clin Res Cardiol 2008, 97:234-243.
4. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-713. Eur Heart J 2003;24:1965-1991.
5. Maron BJ Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 2007, 116:207-216.
6. Sigwart U, Grbic M, Payot M, Essinger A, Sadeghi H Wall motion during balloon occlusion. Ventricular wall motion 1983, 206-210. Georg Thieme, New York (NY). U. Sigwart, P.H. Heinzen (Eds.).
7. Kuhn HJ, Sigwart U Induced septal/nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998, 97:709-710. [Correspondence].
8. Sigwart U, Grbic M, Essinger A, Rivier JL L'effect aigu d'occlusion coronarienne par ballonet de la dilatation transluminale. Schweiz Med Wochenschr 1982, 45:1631. [abstract].
9. Sigwart U Therapie der hypertrophen obstruktiven Kardiomyopathie. Dtsch Med Wochenschr 1997, 122:495.
10. Knight C., Kurbaan A.S., Seggewiss H., Henein M., Gunning M., Harrington D., Fassbender D., Gleichmann U., Sigwart U. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997, 95:2075-2081.
11. Gietzen F, Leuner C, Gerenkamp T, Kuhn H Abnahme der Obstruktion bei hypertrophischer Kardiomyopathie während passagerer Okklusion des ersten Septalastes der linken Koronararterie. Z Kardiol 1994, 83(suppl 1):146. [abstract].
12. Kuhn H, Gietzen F, Leuner C, Gerenkamp T Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: studies to develop a new, catheter-based concept of treatment. Eur Heart J 1997, 18:846-851.
13. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn HJ Acute and long term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999, 20:1342-1354.
14. Brugada P, de Swart H, Smeets JL, Wellens H Transcoronary chemical ablation of ventricular tachycardia. Circulation 1989, 79:475-482.
15. Inoue H., Waller B.F., Zipes D.P. Intracoronary ethyl alcohol or phenol injection ablates aconitine - induced ventricular tachycardia in dogs. J Am Coll Cardiol 1987, 10:1342-1349.